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Abstract 
Carboxyl-terminal binding protein 1 (CtBP1) is a transcriptional co-repressor that represses 
expression of various tumor suppressor genes. In the present study, we identified miR-137 as 
a potential regulator of CtBP1 expression in melanoma cells. Expression of miR-137 in me-
lanoma cell lines was found to inversely correlate with CtBP1 levels. Target Scan predicted a 
putative site for miR-137 within the CtBP1 3′ untranslated region (3′UTR) at nt 710–716, 
which is highly conserved across species. To explore the mechanism of miR-137 targeting 
C t B P 1 ,   w e   p e r f o r m e d   a n   Argonaute 2 (Ago2)-pull down assay, and miR-137 was identified in 
complex with CtBP1 mRNA. miR-137 suppressed CtBP1 3’ UTR luciferase-reporter activity, 
and this effect was lost with deletion of the putative 3’ UTR target-site. Consistent with the 
r e s u l t s   o f   t h e   r e p o r t e r   a s s a y ,   e c t o p i c   e x p r e s s i o n   o f   m i R -137 reduced expression levels of 
CtBP1. Furthermore, expression of miR-137 increased the immediate downstream effectors 
of CtBP1, such as E-cadherin and Bax. The human miR-1 3 7   g e n e   i s   l o c a t e d   a t   c h r o m o s o m e  
1p22, which has previously been determined to be a susceptive region for melanoma. This 
study suggests miR-137 may act as a tumor suppressor by directly targeting CtBP1 to inhibit 
epithelial-mesenchymal transition (EMT) and inducing apoptosis of melanoma cells, thus il-
lustrating a functional link between miR-137 and CtBP1 in melanoma development. 
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Introduction 
MicroRNAs  (miRNAs)  are  highly  conserved, 
small, non-c o d i n g   R N A s   t h a t   p l a y   a   v i t a l   r o l e   i n   d e-
velopment, cell proliferation, differentiation, apopto-
sis, and metabolism. They function by binding to the 
3 ′ U T R   o f   m u l t i p l e   t a r g e t   m R N A s .   I n   m a m m a l s ,  
miRNAs guide  proteins of  the  Argonaut e   f a m i l y   t o  
partially-complementary sequences typically located 
i n   t h e   3 ′ U T R   o f   s p e c i f i c   t a r g e t   m R N A s ,   l e a d i n g   t o  
translational repression or mRNA degradation [1] [2] 
[3]. 
The  identification  of  miRNA  as  the  causative 
force for chronic lymphocytic leukemia opened a new Int. J. Biol. Sci. 2011, 7 
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a v e n u e   i n   t h e   f i e l d   o f   o nc o g e n e s i s .   A   v a r i e t y   o f   c a n-
cers, including  col o n ,   c e n t r a l   n ervous  system,  mela-
noma, prost a t e   a n d   b r e a s t   w e r e   a l l   f o u n d   t o   b e   i n f l u-
enced by the dysregulat i o n   o f   m i R N A s .     m i R -137  is 
located at the region on chromosome 1p22 where loss 
is associated with increased  melanoma risk [4].  With 
the identification of miRNAs as important regulators 
of  gene  express i o n ,   w e   h ypothesized  miR-137  may 
regulate target expression associated with melanoma 
risk.  
Previously  miR-1 3 7   w a s   s h o w n   t o   t a r g e t   t h e  
3 ′ U T R   o f   t h e   k e y   r e g u l a t o r   o f   m e l a n o g e n e s i s   a n d   m e-
lanoma  development,  micropthalmia-associated 
transcription factor (MITF) [5].   C t B P 1   i s   a n o t h e r   p r e-
dicted  tar g e t   o f   m i R -137.  CtBP1  was  identified  as  a 
transcriptional  co-repressor  of  several  tumor  sup-
pressors [6].   C t B P 1   h a s   b e e n   s h o w n  to suppress  the 
transcription of tumor suppressors such as E-cadherin 
in  multiple  cell  lines  [6].  Con-
versely, tumor suppressors, such 
as HIPK2, Ink4a/Arf, and APC, 
target  CtBP1  degradation  to  in-
duce apoptosis [6]. Therefore, we 
studied  the  regulatio n   o f   C t B P 1  
and  its  down-stream  targets  by 
miR-137 in melanoma cell lines.  
Results  
miRNAs  have  emerged  as  post-transcriptional 
regulators  critically  inv o l v e d   i n   t h e   p a t h ogenesis  of 
human cancers. Previously, miR-1 3 7   h a s   b e e n   s h o w n  
to target MITF [5,7].   C t B P 1   i s   a n o t h e r   p r edicted target 
of  miR-137 (Fig. 1a) and we found CtBP1 expression 
in melanoma cell lines was inversely  correlated with 
miR-137 levels; CtBP1 expression in WM278 cells was 
significantly lower than in A375 cells (Fig. 1b) and its 
miR-1 3 7   i s   4   f o l d   h i g h e r   ( F i g .   1 c ) .   T a r g e t   S c a n   r evealed 
t h e   3 ’ U T R   o f   C t B P 1   c o ntains  a  miR-137  site  at  nt 
710-7 1 6   ( F i g .   1 a ) ,   a n d   t h e   m i R -137  binding  site  in 
CtBP1 3’UTR  is  cons e r v e d   f r o m   h u m a n   t o   c h i c k e n  
(Fig. 1d). Predictions of miRNA-mRNA  interactions 
typically rely on bioinformatic algorithms, but these 
algorithms  only  suggest  the  possibility  of  miRNA 
binding and may falsely predict interactions.    
 
 
 
 
 
 
 
F i g u r e   1 . CtBP1 is a predicted target 
for  miR-137. (a) Diagram of CtBP1 
mRNA  depicting  the  predicted 
miR-137 site in the 3’UTR region. (b) 
CtBP1  protein  levels  in  A375  and 
WM278 cells. Tubulin was used as a 
loading control. (c) miR-137 levels of 
the A375 and WM278 cells. miR-137 
level was determined by the Taqman 
assay. Data were normalized to the 
18s mRNA.    Samples were assayed in 
triplicate for each experiment and at 
least two independent experiments 
were performed.  Data are presented 
as mean + S E M   f r o m   a   r e p r e s e n t ative 
experiment. (d) Conservation of the 
miR-137  site  in  CtBP1  in  different 
species. 
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We  expressed  miR-137  in  HEK293  cells  and 
a n a l y z e d   t h e   m R N A s   a s s o c i a t e d   w i t h   A g o 2   u s i n g   a  
biochemical  approach  based  on  the  functional 
co-c o m p l e x   o f   A g o 2   w i t h   m i R N A   a n d   i t s   t a r g e t  
mRNA [8] to gain insight into the predicted miR-137 
targeting of CtBP1. qRT-PCR shows less binding of a 
non-target  mRNA  in  the  presenc e   o r   a b s e n c e   o f  
miR-1 3 7 ,   b u t   C t B P 1   m R N A   b i n d i n g   t o   A g o 2   i n   t h e  
presence of miR-1 3 7   w a s   i n c r e a s e d   3   f o l d   c o m p a r e d   t o  
a control oligo (Fig. 2a).  
 
 
 
 
Figure 2. miR-1 3 7   t a r g e t s   C t B P 1   i n   m e l a n o m a   c e l l s .   ( a )   C t B P 1   m R N A   b i n d i n g   to the Ago2 complex in the presence of 
miR-137. HEK293 cells were transfected with Ago2 in the presence (Ago2+miR137) and absence (Ago2) of miR-137, and 
the Ago2-complex was pulled down. Primer sets for CtBP1 and 18S (Non-target) were used to qRT-PCR-amplify the pull 
down samples. (b) miR-137 decreases CtBP1 3’UTR-reporter. A375 cell were transfected with luciferase constructs fused 
to CtBP1 3’UTR, either the wild type (WT) or the deletion of the putative miR-137 targeting site, along with control oligo 
(SC)   o r   m i R -137 by Lipofecatmine 2000 in suspension and were immediately transferred
 to 0.5 ml DMEM with FBS and 
i n c u b a t e d   a t   3 7 ° C   f o r   4 8   h   b e f o r e   l u c i f e r a s e   a s s a y .     R e l a t i v e   l u c i f e r a s e  expression levels were determined by normalizing 
with internal controls, values were expressed as ratios to the control sample.  Samples were assayed in triplicate for each 
experiment and at least two independent experiments were performed.  Data are presented as mean + SEM from a rep-
resentative experiment. (c) miR-137 decreases CtBP1 expression. A375   c e l l   w e r e   t r a n s f e c t e d   w i t h   t h e   c o n t r o l   o l i g o   ( S C )   o r  
miR-137 by Lipofecatmine 2000 in suspension and were immediately transferred
 t o   0 . 5   m l   D M E M   w i t h   F B S   a n d  incubated at 
37°C for 48 h before western blotting. Tubulin was used as a loading control. (d) miR-137 down-regulates E-cadherin and 
Bax genes. A375 cell were transfected with the control oligo or miR-137 and incubated at 37°C for 48 h before qRT-PCR 
for the mRNA levels of E-cadherin and Bax. 
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T o   a s s e s s   t h e   c o n t r i b u t i o n   o f   t h e   p r e d i c t e d  
miR-137  binding  site,  we  constructed  lucife-
rase-r e p o r t e r   g e n e s   w i t h   t h e   C t B P 1   3 ’ U T R   w i t h   a n d  
without  deletion  at  the  miR-137 binding region and 
tested their expression with miR-137  addition.  Con-
sistent  with  binding  data,  miR-137  transfection  re-
pressed luciferase expression when CtBP1 3’UTR was 
fused to the luciferase reporter (Fig. 2b).  Supporting 
t h e   r o l e   o f   t h e   p u t a t i v e   m i R -137  targeting  site  on 
CtBP1,  miR-1 3 7   t r a n s f e c t i o n   d i d   n o t   d e c r e a s e   l u c i f e-
r a s e   e x p r e s s i o n   w h e n   f u s e d   w i t h   C t B P 1   3 ’ U T R   h a r-
b o r i n g   t h e   d e l e t i o n   ( F i g   2 b ) .   T h e s e   d a t a   s u g g e s t   t h a t  
miR-137  down-regulates  CtBP1,  probably  through 
specific  interaction  with  the  putative  site  at  CtBP1’s 
3’UTR, and CtBP1 is a direct target for miR-137. 
To  explore  if  miR-137  controls  protein  expres-
sion levels of CtBP1 in melanoma cells, we transfected 
melanoma  cell  line  A375  that  has  relatively  high 
C t B P 1   e x p r e s s i o n   w i t h   m i R -137 and analyzed CtBP1 
protein  by  western  blotting.  As  shown  in  Fig.    2c, 
over-expression  of  miR-137  led  to  a  significant  de-
c r e a s e   i n   C t B P 1   p r o t e i n   c o m p a r e d   w i t h   t h e   c o n t r o l .  
Therefore, we conclude miR-137 plays a critical role in 
CtBP1 expression.  
We studied the function of human miRNAs and 
to determine if the downstream targets of CtBP1 are 
affected  by  ectopic  expression  of  miR-137  by  per-
forming  qRT-P C R   t o   a s s e s s   m R N A   l e v e l s   o f  
E-c a d h e r i n   a n d   B a x   i n   A 3 7 5   c e l l s   t r a n s f e c t e d   w i t h  
miR-137 or control oligo. As shown in Fig. 2d, mRNA 
leve l s   o f   E -cadherin and Bax increased with miR-137 
expression,  mimicking  the  functional  outcome  of 
C t B P 1   k n o c k d o w n .   T h i s   d a t a   s u g g e s t s   t h e   f u n c t i o n   o f  
miR-1 3 7   i n   m e l a n o m a   i s ,   a t   l e a s t   i n   p a r t ,   t h r o u g h   i t s  
regulation of CtBP1. 
Discussion 
miRNAs  are  involved  in   m a n y   d i f f e r e n t   c e l l  
processes including cell-cycle regulation, differentia-
tion,  proliferation  and  apoptosis  [reviewed  in  [9]]. 
I m p r o p e r   e x p r e s s i o n   o f   m i R N A   g e n e s   i s   s e e n   i n   b o t h  
benign and malignant cancers, and miRNA genes can 
a c t   a s   t u m o r   s u p p r e s s o r s   o r   o n c o g e n e s .   m i R N A   e x-
p r e s s i o n   p r o f i l e s   c a n   b e   u s e d   t o   c l a s s i f y   s o l i d   t u m o r s  
[10] and previous study has shown that miRNA ex-
pression differs between melanoma cell lines [11]. The 
incidence of malignant melanoma is increasing at a 
g r e a t e r   r a t e   t h a n   a n y   o t h e r   c a n c e r   t y p e ,   t h u s   i t   r e-
mains  a  significant  public  health  threat.  Molecular 
mechanisms  involved  in  the  development  of  mela-
noma  are  being  intensely  researched.  Research  by 
others found miR-137 is located at chromosome 1p22, 
a melanoma susceptibility hot spot. In this study, we 
identified CtBP1 as a novel target for miR-137. Given 
t h e   c r i t i c a l   r o l e   o f   C t B P 1   i n   t u m o r i g e n e s i s ,   w e   h y p o-
thesize that miR-137 might function as a tumor sup-
p r e s s o r   i n   m e l a n o m a   b y   t a r g e t i n g   C t B P 1 .   O u r   d a t a  
s h o w i n g   r e g u l a t i o n   o f   C t B P 1   d o w n -s t r e a m   g e n e s   s u c h  
a s   E -c a d h e r i n   a n d   B a x   b y   m i R -137 further support this 
n o t i o n .   O u r   f u t u r e   s t u d i e s   w i l l   a s s e s s   i f   o t h e r   C t B P 1 
t a r g e t s ,   s u c h   a s   P T E N   a n d   p 5 3 ,   a r e   c o n t r o l l e d   b y  
miR-1 3 7 ,   t h u s   f u r t h e r   l i n k i n g   t h e   m i R -137-CtBP1 axis 
with melanoma development.  
Numerous  studies  characterizing  expression 
p r o f i l e s   o f   m i R N A s   i n   c a n c e r   h a v e   s h o w n  
down-r e g u l a t i o n   o f   m i R N A   e x p r e s s i o n   i n   c a ncer cell 
lines  compared  with  normal  tissues  [12]  [13].  Fur-
thermore, the recent identification of altered miRNA 
e x p r e s s i o n   i n   a   v a r i e t y   o f   c a n c e r   s i t e s   h a s   c o n f i r m e d  
t h i s   i s   a n o t h e r   c l a s s   o f   m o l e c u l e s   c a p a b l e   o f   f u n c t i o n-
ing as tumor suppressors or oncogenes [14]. miRNAs 
b i n d i n g   t o   t h e   t a r g e t   g e n e   3 ′ U T R   i s   u s u a l l y   i m p e r f e c t  
and therefore multiple targets have been identified for 
a   s i n g l e   m i R N A .   A s   m e n t i o n e d   a b o v e ,   m i R -137  in 
melanoma cells also targets MITF, believed to play a 
significant  role  in  melanoma-genesis  [15,16].  This 
mode  of  regulation  could  be  used  as  a  therapeutic 
strategy by manipulating the miRNA targeting mul-
tiple gene pathways for a synergistic effect. 
In oral squamous carcinoma  miR-137 is silenced 
by hypermethylation [17].   I n   r e c t a l   c a n c e r   m i R -137 is 
up-regulated after preoperative capecitabine chemo-
radiotherapy  [18].  miR-137, along with miR-124,  in-
duce  differentiation  of  glioblastoma  multi-
forme-derived  stem  cells  and  induce  glioblastoma 
multiforme  cell  cycle  arrest,  which  was  associated 
with decreased expression of cyclin-dependent kinase 
6  (CDK6)  and  phosphorylated  retinoblastoma  pro-
teins  [19].  In  addition,  the  ectopic  transfection  of 
miR-1 3 7   i n t o   a n   o r a l   s q u a m o u s   c e l l   c a r c i n o m a   s i g n i f-
i c a n t l y   r e d u c e s   c e l l   g r o w t h ,   b y   d o w n -r e g u l a t i o n   o f   t h e  
translation of CDK6 or E2F6 transcription factors [17]. 
Recently, miR-1 3 7   w a s   s h o w n   t o   t a r g e t   C D C 4 2   i n   c o-
lorectal cells, inducing cell cycle G1 arrest and inhi-
biting  invasion  [20].   T h e   i d e n t i f i c a t i o n   o f   t h e   m u l-
ti-functional transcriptional co-repressor  CtBP1  as  a 
miR-137  target  further  highlights  the  importance  of 
miR-137 loss/silence in  various  human  tumors.  De-
termining if miR-137  regulates  CtBP1  and  other  tar-
gets in cancer patients awaits further investigation. 
Acknowledgement 
T h i s   w o r k   w a s   s u p p o r t e d   b y   t h e   N I H   g r a n t  
R01CA115468 (to Q.Z.). 
Conflict of Interests 
The authors declare no conflict of interests. Int. J. Biol. Sci. 2011, 7 
 
http://www.biolsci.org 
137 
References 
1.  Lee Y, Jeon K ,   L e e   J T ,   K i m   S ,   K i m   V N .   M i c r o R N A   m a t u r a t i o n :  
stepwise  processing  and  subcellular  localization.  Embo  J 
2002;21(17):4663-4670. 
2.  C h e n   K ,   R a j e w s k y   N .   T h e   e v o l u t i o n   o f   g e n e   r e g u l a t i o n   b y  
transcription  factors  and  microRNAs.  Nat  Rev  Genet 
2007;8(2):93-103. 
3.  Pillai RS, Bhattacharyya SN, Filipowicz W. Repression of pro-
tein synthesis by miRNAs: how many mechanisms? Trends Cell 
Biol 2007;17(3):118-126. 
4.  Walker GJ, Indsto JO, Sood R et al. Deletion mapping suggests 
that the 1p22 melanoma susceptibility gene is   a   t u m o r   s u p-
pressor  localized  to  a  9-Mb  interval.  Genes  Chromosomes 
Cancer 2004;41(1):56-64. 
5.  B e m i s   L T ,   C h e n   R ,   A m a t o   C M   e t   a l .   M i c r o R N A -137 targets 
microphthalmia-associated  transcription  factor  in  melanoma 
cell lines. Cancer Res 2008;68(5):1362-1368. 
6.  Chinnadurai G. The transcriptional corepressor CtBP: a foe of 
multiple tumor suppressors. Cancer Res 2009;69(3):731-734. 
7.  Haflidadottir BS, Bergsteinsdottir K, Praetorius C, Steingrims-
s o n   E .   m i R -1 4 8   r e g u l a t e s   M i t f   i n   m e l a n o m a   c e l l s .   P L o S   O n e   
2010;5(7):e11574. 
8.  B e i t z i n g e r   M ,   P e t e r s   L ,   Z h u   J Y ,   K r e m m e r   E ,   M e i s t e r   G .   I d e n t i-
fication of human microRNA targets from isolated argonaute 
protein complexes. RNA Biol 2007;4(2):76-84. 
9.  Mueller DW, Bosserhoff AK. Role of miRNAs in the progres-
sion of malignant melanoma. Br J Cancer 2009;101(4):551-556. 
10.  L u   J ,   G e t z   G ,   M i s k a   E A   e t   a l .   M i c r o R N A   e x p r e s s i o n   p r o f i l e s  
classify human cancers. Nature 2005;435(7043):834-838. 
11.  Gaur A, Jewell DA, Liang Y et al. Characterization of micro-
RNA expression levels and their biological correlates in human 
cancer cell lines. Cancer Res 2007;67(6):2456-2468. 
12.  C a l i n   G A ,   C r o c e   C M .   M i c r o R N A   s i g n a t u r e s   i n   h u m a n   c a n c e r s .  
Nat Rev Cancer 2006;6(11):857-866. 
13.  G a r z o n   R ,   F a b b r i   M ,   C i m m i n o   A ,   C a l i n   G A ,   C r o c e   C M .   M i-
croRNA e x p r e s s i o n   a n d   f u n c t i o n   i n   c a n c e r .   T r e n d s   M o l   M e d  
2006;12(12):580-587. 
14.  Z h a n g   B ,   P a n   X ,   C o b b   G P ,   A n d e r s o n   T A .   m i c r o R N A s   a s   o n c o-
genes and tumor suppressors. Dev Biol 2007;302(1):1-12. 
15.  Du J, Widlund HR, Horstmann MA et al. Critical role of CDK2 
for  melanoma growth linked to its melanocyte-specific  tran-
scriptional regulation by MITF. Cancer Cell 2004;6(6):565-576. 
16.  McGill GG, Horstmann M, Widlund HR et al. Bcl2 regulation 
by  the  melanocyte  master  regulator  Mitf  modulates  lineage 
survival and melanoma cell viability. Cell 2002;109(6):707-718. 
17.  K o z a k i   K ,   I m o t o   I ,   M o g i   S ,   O m u r a   K ,   I n a z a w a   J .   E x p l o r a t i o n   o f  
tumor-suppressive microRNAs silenced by DNA hypermethy-
lation in oral cancer. Cancer Res 2008;68(7):2094-2105. 
18.  Svoboda M, Izakovicova Holla L, S e f r   R   e t   a l .   M i c r o -RNAs 
miR125b and miR137 are frequently upregulated in response to 
capecitabine  chemoradiotherapy  of  rectal  cancer.  Int  J  Oncol 
2008;33(3):541-547. 
19.  S i l b e r   J ,   L i m   D A ,   P e t r i t s c h   C   e t   a l .   m i R -124 and miR-137 inhibit 
proliferation of glioblastoma multiforme cells and induce dif-
ferentiation of brain tumor stem cells. BMC Med 2008;6:14. 
20.  L i u   M ,   L a n g   N ,   Q i u   M   e t   a l .   m i R -137 targets Cdc42 expression, 
induces cell cycle G1 arrest and inhibits invasion in colorectal 
cancer cells. Int J Cancer 2010; [Epub ahead of print]. 